Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
SYRA$0.88-0.01(-0.68%)Syra Health To Announce Third Quarter 2026 Financial Results Syra Health Corp. (OTCQB: SYRA), ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through ...[9:06:00 AM ET]DFIN$54.21-1.31(-2.36%)DFIN Announces Venue® MCP Connector, Bringing Secure AI Access to High-Stakes Deal Workflows Donnelley Financial Solutions (NYSE: DFIN), a leading global provider of financial regulatory and compliance solutions and the top SEC filing agent,...[9:05:00 AM ET]AWK$142.08-0.67(-0.47%)American Water Contributes Expertise at California Water Association 2026 Summit American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., will join important conversations and contribute...[9:03:00 AM ET]TFC$48.91+0.47(+0.97%)Truist names Alex Bartlett regional president for Greater Washington and Maryland Truist Financial Corporation (NYSE: TFC) today announced Alex Bartlett has been named regional president for Greater Washington and Maryland. A...[9:03:00 AM ET]MKTW$19.58+0.75(+3.98%)MarketWise, Inc. Declares Quarterly Dividend on Class A Common Stock of $0.45 Per Share[9:00:14 AM ET]UFPI$80.93-0.30(-0.37%)UFP Packaging Expands Gulf Coast Pallet Network with Acquisition of Apache Products UFP Packaging, a division of UFP Industries (Nasdaq: UFPI), announced this week the acquisition of Apache Products, Inc., a pallet producer based in...[9:00:00 AM ET]THFF$77.70+1.24(+1.62%)First Financial Corporation Reports Third Quarter Results[9:00:00 AM ET]FTNT$181.84-1.49(-0.81%)Fortinet Expands Unified SASE to Simplify Microbranch Security[9:00:00 AM ET]VELO$6.61+0.12(+1.85%)Velo3D to Announce Third Quarter 2026 Results on November 10, 2026 Velo3D, Inc. (Nasdaq: VELO), a leading metal additive manufacturing technology company, today announced that it will release its third quarter 2026...[9:00:00 AM ET]CPB$20.53-0.10(-0.48%)Campbell's® Marks Five Years of Sides Season™ with Its Annual State of the Sides Report Campbell's officially kicked off Sides Season™ with the release of its 2026 State of the Sides Report. Now in its fifth year, the report offers a...[9:00:00 AM ET]COCO$55.80-0.73(-1.30%)Vita Coco® Introduces Vita Coco Kids, Designed for the Next Generation of Coconut Water Drinkers and Available Exclusively at Select Walmart Locations[9:00:00 AM ET]TENB$47.55-0.66(-1.37%)Tenable Selected by Atos to Power Continuous Threat Exposure Management Program[9:00:00 AM ET]PLUR$1.23+0.11(+9.82%)Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments[9:00:00 AM ET]

GMAB · NASDAQ

Genmab A/S

$44.44 -0.20 (-0.45%)

Company overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB for treating solid tumors; epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$27.3B
Employees
2,638
Headquarters
Copenhagen
Website
genmab.com
CEO
Jan van de Winkel
Listed
June 1, 2009
P/E
33.49
Dividend yield
0.00%

Company financials

Revenue
$3.9B
Gross profit
$3.6B
Operating income
$1.3B
EBITDA
$1.4B
Net income
$821M
EPS
$1.33
Total assets
$12.4B
Total debt
$5.4B
Gross margin
93.31%
Net margin
21.05%
Earnings yield
2.99%

Price chart

22.7528.6434.5340.4346.32
GMAB 1D NASDAQ O45.13H45.45L44.08C44.64+0.85 (+1.94%)Vol1.91M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
GMABGenmab A/S Stock news Genmab's Encouraging Oncology Data Boosts Investor Optimism Benzinga
GMABGenmab A/S Press release Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market GlobeNewswire
GMABGenmab A/S Stock news Genmab Shares Jump After Positive Cancer Study Results WSJ
GMABGenmab A/S Press release Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma GlobeNewswire
GMABGenmab A/S Stock news Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer GuruFocus
GMABGenmab A/S Press release Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer GlobeNewswire
GMABGenmab A/S Stock news Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer GuruFocus
GMABGenmab A/S Stock news Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer GuruFocus
GMABGenmab A/S Press release Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer GlobeNewswire
GMABGenmab A/S Press release Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer GlobeNewswire
GMABGenmab A/S Press release Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $4. PR Newswire
GMABGenmab A/S Press release Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 GlobeNewswire
GMABGenmab A/S Stock news Genmab: Epkinly Shines In Phase 3 DLBCL Trial Seeking Alpha
GMABGenmab A/S Stock news Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? Zacks Investment Research
GMABGenmab A/S Stock news Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug WSJ
GMABGenmab A/S Stock news Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell GuruFocus
GMABGenmab A/S Stock news AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell GuruFocus
GMABGenmab A/S Press release AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma PRNewsWire
GMABGenmab A/S Press release Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma GlobeNewsWire
GMABGenmab A/S Stock news Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer GuruFocus
See more
FAQ

Questions about Genmab A/S

What does Genmab A/S do?
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB for treating solid tumors; epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.
What is GMAB's market cap?
Genmab A/S (GMAB) is a listed stock with a live quote. The latest market cap on this page is $27.3B.
Where is Genmab A/S headquartered?
Genmab A/S is headquartered in Copenhagen.
How do I get GMAB news from the API?
Call GET /v1/news?tickers=GMAB. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does GMAB news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for GMAB, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the GMAB price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs